1 Predicting mortality due to SARS-CoV-2: A mechanistic score

2 relating obesity and diabetes to COVID-19 outcomes in Mexico

- 3 Omar Yaxmehen Bello-Chavolla^{1,2*}, Jessica Paola Bahena-López³, Neftali Eduardo Antonio-
- 4 Villa^{1,3}, Arsenio Vargas-Vázquez^{1,3}, Armando González-Díaz⁴, Alejandro Márquez-Salinas^{2,3},
- 5 Carlos A. Fermín-Martínez^{1,3}, J. Jesús Naveja⁵, Carlos A. Aguilar-Salinas^{1,6,7}
- ¹Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias
- 7 Médicas y Nutrición Salvador Zubirán. ²Division of Research, Instituto Nacional de Geriatría.
- ³MD/PhD (PECEM), Faculty of Medicine, National Autonomous University of Mexico.
- ⁴Universidad Nacional Autónoma de México. ⁵Instituto de Química, Universidad Nacional
- 10 Autónoma de México. ⁶Department of Endocrinolgy and Metabolism. Instituto Nacional de
- 11 Ciencias Médicas y Nutrición Salvador Zubirán. ⁷Tecnologico de Monterrey, Escuela de
- 12 Medicina y Ciencias de la Salud.
- 13 **Short title:** COVID-19 mortality, diabetes and obesity in Mexico

14 Corresponding authors

- 15 Omar Yaxmehen Bello-Chavolla. Division of Research. Instituto Nacional Geriatría. Anillo
- 16 Perif. 2767, San Jerónimo Lídice, La Magdalena Contreras, 10200, Mexico City, Mexico.
- 17 Phone: +52 (55) 5548486885. E-mail: oyaxbell@yahoo.com.mx
- 18 Carlos A. Aguilar-Salinas. Unidad de Investigación de Enfermedades Metabólicas. Instituto
- 19 Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Vasco de Quiroga 15. CP
- 20 14080; Tlalpan, Distrito Federal, México. Phone: +52(55)54870900, 5703. E-mail:
- 21 <u>caguilarsalinas@yahoo.com</u>
- 22 **CONFLICT OF INTERESTS:** Nothing to disclose.
- 23 **FUNDING:** This research received no specific funding

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

ABSTRACT (250 WORDS) BACKGROUND: The SARS-CoV-2 outbreak poses challenge to healthcare systems due to high complication rates in patients with cardiometabolic diseases. Here, we identify risk factors and propose a clinical score to predict COVID-19 lethality, including specific factors for diabetes and obesity and its role in improving risk prediction. METHODS: We obtained data of confirmed and negative COVID-19 cases and their demographic and health characteristics from the General Directorate of Epidemiology of Mexican Ministry of Health. We investigated specific risk factors associated to COVID-19 positivity and mortality and explored the impact of diabetes and obesity on modifying COVID-19 related lethality. Finally, we built a clinical score to predict COVID-19 lethality. RESULTS: Among 71,103 subjects at April 27th, 2020, we observed 15,529 subjects with SARS-CoV-2 and 1,434 deaths. Risk factors for lethality in COVID-19 includes early-onset diabetes obesity, COPD, advanced age, immunosuppression, and CKD; we observed that obesity mediates 45.5% of the effect of diabetes on COVID-19 lethality. Early-onset diabetes conferred an increased risk of hospitalization and obesity conferred an increased risk for ICU admission and intubation. Our predictive score for COVID-19 lethality included age ≥65 years, diabetes, early-onset diabetes, obesity, age <40 years, CKD, hypertension, pregnancy and immunosuppression and significantly discriminates lethal from non-lethal COVID-19 cases (cstatistic=0.830). **RESULTS:** Here, we propose a mechanistic approach to evaluate risk for complications and lethality attributable to COVID-19 considering the effect of obesity and diabetes in Mexico. Our score offers a clinical tool for quick determination of high-risk susceptibility patients in a first contact scenario.

Keywords: COVID-19; SARS-CoV-2; Diabetes; Obesity, Lethality; Mexico

INTRODUCTION

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

The first cases of SARS-CoV-2 infection in Mexico were reported at the end of February [1]; since then, the number of COVID-19 cases have been steadily increasing, with most fatal cases being associated with the presence of comorbidity and, particularly, cardiometabolic comorbidities. A high prevalence of cardiometabolic diseases worldwide represents a challenge during the COVID-19 epidemic. An elevated number of patients with SARS-CoV-2 infection have a preexisting disease such as obesity, hypertension, cardiovascular disease, diabetes, chronic respiratory disease or cancer [2,3]. Diabetes mellitus and obesity represent a large share of the cardiometabolic morbidity burden of the region [4]; moreover, most cases of diabetes remain either undiagnosed or lack adequate glycemic control, posing them at risk of increased COVID-19 severity. Despite several reports evaluating the burden of comorbidities including obesity, diabetes and hypertension on the clinical course of COVID-19, the joint role of obesity and diabetes in modifying COVID-19 outcomes has not been fully explored [5]. Several studies have demonstrated a higher susceptibility to acute respiratory infectious diseases in people with diabetes [6]. Moreover, diabetes and obesity have been described as independent risk factors for severe pulmonary infection [7,8]. Obesity influences the clinical outcomes during an acute severe respiratory distress syndrome (ASRDS); it has been proposed as a protective factor for mortality following lung injury (due to reverse causality) or as a cause of mortality and adverse clinical outcomes for severe influenza cases (due to mechanical and immunologic factor). In the cases of the COVID-19 outbreak, obesity has been consistently associated with adverse outcomes [9,10]. Furthermore, a large proportion of obesity cases in Mexico lives in geographical areas of increased social vulnerability, which poses a structural inequality that might also increase mortality for COVID-19 associated to both diabetes and obesity [11]. Chronic inflammation in obesity might worsen the acute inflammatory response triggered by SARS-Cov2 infection, which might be associated to a

cytokine release syndrome [5,12]. Here, we investigate the role of both diabetes and obesity in determining propensity for SARS-CoV-2 infection and its associated clinical outcomes including disease severity and COVID-19 lethality; using these associations, we further construct a clinically useful predictive model for COVID-19 mortality using national epidemiological surveillance data from Mexico.

METHODS

75

76

77

78

79

- 81 <u>Data sources</u>
- 82 We extracted this dataset from the General Directorate of Epidemiology of the Mexican
- 83 Ministry of Heath, which is an open-source dataset comprising daily updated data of
- 84 suspected COVID-19 cases which have been confirmed with a positive test for SARS-CoV-2
- certified by the National Institute for Diagnosis and Epidemiological Referral [13].
- 86 Definitions of suspected and confirmed COVID-19 cases
- 87 The Ministry of Health defines a suspected COVID-19 case as an individual of any age whom
- 88 in the last 7 days has presented cough, fever or headache (at least two), accompanied by
- 89 either dyspnea, arthralgias, myalgias, sore throat, rhinorrhea, conjunctivitis or chest pain.
- 90 Amongst these suspected cases, the Ministry of Health establishes two protocols for case
- 91 confirmation: 1) SARS-CoV-2 testing is done widespread for suspected COVID-19 cases with
- 92 severe acute respiratory infection with signs of breathing difficulty or deaths in suspected
- 93 COVID-19 cases, 2) for all other suspected cases, a sentinel surveillance model is being
- 94 utilized, whereby 475 health facilities comprise a nationally representative sample which
- 95 samples ~10% of mild outpatient cases and all suspected severe acute respiratory infection
- 96 [14]. Demographic and health data are collected and uploaded to the epidemiologic
- 97 surveillance database by personnel from the corresponding individual facility.
- 98 Variables definitions
- 99 Available information for all confirmed, negative and suspected COVID-19 cases includes
- age, sex, nationality, state and municipality where the case was detected, immigration status

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

as well as identification of individuals who speak indigenous languages from Mexico. Health information includes status of diabetes, obesity, chronic obstructive pulmonary disease (COPD), immunosuppression, pregnancy, arterial hypertension, cardiovascular disease, chronic kidney disease (CKD) and asthma. Date of symptom onset, hospital admission and death are available for all cases as well as treatment status (outpatient or hospitalized), information regarding diagnosis of pneumonia, ICU admission and whether the patient required invasive mechanical ventilation. Statistical analysis Comorbidities associated to SARS-CoV-2 positivity We investigated the association of demographic and health data associated with SARS-CoV-2 positivity using logistic regression analyses, excluding individuals who were only suspected but unconfirmed cases of COVID-19. Next, we stratified these analyses for individuals with only diabetes or only obesity to identify specific risk factors within these populations, especially focusing on individuals who were <40 years and likely acquired the disease early. COVID-19 mortality risk In order to investigate risk factors predictive of COVID-19 related 30-day lethality, we fitted Cox Proportional risk regression models estimating time from symptom onset up to death or censoring, whichever occurred first in cases with confirmed positivity for SARS-CoV-2. To identify diabetes and obesity-specific risk factors, we carried out stratified analyses. Given the availability of SARS-CoV2 negative cases within the dataset, we fitted Cox models for 30-day mortality which included SARS-CoV-2 positivity as an interaction term with different comorbidities, hypothesizing that some factors increase mortality risk specifically for COVID-19. Finally, we fitted a logistic regression model only for mortality cases to evaluate associations with lethality rates in COVID-19 related and non-related deaths. Influence of obesity and diabetes in COVID-19 related outcomes

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

Finally, we estimated factors associated to admission to hospital facilities, intensive care units (ICUs) and requirements for mechanical ventilation in all confirmed COVID-19 cases using logistic regression. To identify specific factors for all COVID-19 and non-COVID-19 patients related to outcomes, we included interaction effects with comorbidities factors; we also performed Kaplan-Meier analyses to identify the role of comorbidities in modifying lethality risk in individuals with diabetes and obesity and compared across categories using Breslow-Cox tests. Finally, we performed causal-mediation analyses with causally-ordered mediators using a previously validated approach to investigate whether obesity mediates the decreases COVID-19 survival attributable to diabetes, particularly in early-onset cases <40 years [15]. Mechanistic mortality risk score for COVID-19 Finally, we constructed a clinically useful model to predict 30-day mortality in COVID-19 cases that might be useful to apply in primary care facilities, including variables and interactions which were identified in mortality analyses. Points were assigned by standardizing all β coefficients with the minimum absolute β coefficient obtained from Cox regression. Points were stratified according to categories of Low risk (≤0), Mild risk (1-3), Moderate risk (4-6), High risk (7-9) and very high risk (≥10). Risk across categories was verifies using Kaplan-Meier analyses. C-statistics and Dxy values were corrected for overoptimism using k-fold cross-validation (k=10) using the rms R package. A p-value <0.05 was considered as statistical significance threshold. All analyses were performed using R software version 3.6.2. **RESULTS** COVID-19 cases in Mexico At the time of writing this report (April 27th, 2020), a total of 71,103 subjects had been treated initially as suspected COVID-19 cases. Amongst them, 15,529 had been confirmed with as positive and 46,079 tested negatives for SARS-CoV-2 infection; additionally, 8,477 cases were still being studied as suspected cases pending testing reports. Amongst confirmed

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

cases, 1,434 deaths were reported (9.2%) whilst 881 deaths were SARS-CoV-2 negative cases (1.9%) and 137 deaths of suspected but unconfirmed cases (1.6%) had been reported. Compared to SARS-CoV-2 negative cases, confirmed cases were older, predominantly male (1.35:1 ratio), had higher rates of hospitalization and showed a higher prevalence of diabetes. hypertension and obesity, but less CKD. SARS-CoV-2 cases were also more likely to be treated as inpatients and had higher rates of ICU admission and requirements for invasive ventilation compared to negative cases (**Table 1**). Factors associated with COVID-19 positivity We investigated cases related to COVID-19 positivity within Mexico. We found that risk of SARS-CoV-2 positivity was higher with diabetes, hypertension, COPD, immunosuppression, CKD, obesity, age >65 and male sex (Supplementary Figure 1). When assessing age, we observed reduced odds of SARS-CoV-2 positivity in patients younger than age 40 and, in contrast, when exploring its interaction with diabetes, we observed an increased probability of SARS-CoV-2 infection. In stratified models, we observed that for patients with diabetes, SARS-CoV-2 positivity was associated with obesity, male sex and an interaction effect was observed between obesity and having less than 40 years; for patients with obesity, diabetes and male sex were also significant. Predictors for COVID-19 related 30-day mortality We identified that COVID-19 cases were associated with a near four-fold increase in mortality due to acute respiratory infection (HR 3.864, 95%CI 3.501-4.264) compared to non-COVID-19 cases. Of interest, the only comorbidity which conferred increased lethality risk exclusively for COVID-19 compared to non-COVID-19 was obesity (HR 1.567, 95%CI 1.273-1.928, Figure 1A). Factors associated to increased lethality in COVID-19 cases were age >65 years, diabetes mellitus, obesity, CKD, COPD, immunosuppression and hypertension (Figure **1B**). We searched for an interaction between diabetes mellitus and age <40 years adjusted

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

for sex and obesity; a higher mortality risk was found for early onset diabetes cases (HR 2.764, 95%CI 1.718-4.447). COVID-19 in patients with diabetes mellitus Confirmed COVID-19 cases with diabetes had a mean age of 56.9 (±12.9) years and were predominantly male. This population had particularly higher mortality rate (10.0% vs. 1.6%), hospitalization and confirmed pneumonia compared with those without diabetes. When stratifying mortality for those with early onset diabetes (<40 years) had higher mortality rates compared to individuals <40 years without diabetes (17.1% vs. 4.6%); similarly, those aged >65 years had lower rates compared to those <65 years with diabetes (23.8% vs. 29.7%). As expected, obesity, hypertension, COPD, CKD, CVD, immunosuppression and asthma were also more prevalent in this population. Interestingly, we observed no significant differences in ICU admission and requirements for mechanical ventilation between subjects with and without diabetes (Supplementary table 1). In patients with diabetes mellitus, COVID-19 related mortality was higher in those with concomitant immunosuppression, COPD, CKD and those aged >65 years (Figure 1C). When assessing the role of comorbidities, COVID-19 patients with diabetes, coexistent obesity, those with early onset diabetes (<40 years) or an increase in the number of comorbidities had increased risk of COVID-19 lethality (Breslow test p<0.001, Figure 2). When comparing cases with and without COVID-19 amongst patients with diabetes mellitus, only obesity displayed a significant interaction with COVID-19 (HR 1.449 95%CI 1.071-1.960) with diabetes after adjustment for age, sex and comorbidities (Supplementary Figure 2). COVID-19 in patients with obesity Similar to patients with diabetes, confirmed COVID-19 cases with obesity had particularly higher rates of mortality (13.6% vs. 8.17%), hospitalization and confirmed pneumonia. Furthermore, patients with obesity also had higher rates of ICU admission (13.2% vs. 10.5%) and were more likely to be intubated (13.1% vs. 10.3%). As expected, diabetes,

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

hypertension, COPD, smoking, CVD and asthma were also more prevalent in patients with obesity (Supplementary table 2). As previously mentioned, obesity was identified as a risk factor which displayed differential risk for COVID-19 infection, specific risk factors for lethality in obese patients with COVID-19 infection immunosuppression and age >65 (Figure 1D); overall, COVID-19 increased risk of mortality in obesity nearly six-fold (HR 5.954, 95%CI 4.939-7.178). The addition of obesity to any number of comorbidities significantly increased the risk for COVID-19 lethality (Breslow test p<0.001, Figure 2-C). Using causally ordered mediation analysis we investigated whether the effect of diabetes (E) on COVID-19 related lethality was partially mediated by obesity (M); the direct effect of diabetes on COVID-19 lethality was significant (Δ_{F1} Y=1.72, 95%Cl 1.54-1.93) as was the indirect effect of obesity $(\Delta_{M1,\gamma})$ = 1.44, 95%CI: 1.32-1.58), representing 45.5% of the total effect of diabetes. COVID-19 outcomes and comorbidities Given the increased risk of diabetes and obesity in modifying COVID-19 related lethality, a secondary objective of our study was to investigate its associations with inpatient outcomes, including hospitalization rate, ICU admission and requirement for mechanical ventilation. In general, early-onset diabetes patients and those with obesity had higher risk of hospitalization, whilst patients with obesity also had increased risk for ICU admission and required intubation. Patients with diabetes mellitus overall had higher risk of hospitalization with no significant additional risk of ICU admission and intubation (Figure 3). Mechanistic score for mortality in COVID-19 Using the identified predictors for mortality and the observed interaction for early-onset diabetes, we designed a predictive score for COVID-19 mortality using Cox regression using a random split of 80% of the dataset stratified my mortality (n=12,424, deaths=1,137). We identified as significant predictors age>65 years, diabetes mellitus, obesity, CKD, COVID-19 related pneumonia, COPD, pregnancy and immunosuppression (Table 2); age<40 was a protective factor which was modified by its interaction with T2D (R²=0.160, C-statistic 0.828,

 D_{xy} =0.656); assigning the point system did not significantly reduce the model's performance (R²=0.159, C-statistic=0.829, D_{xy} =0.657). Finally, category stratification reduced only moderately performance statistics (R²=0.157, C-statistic=0.816, D_{xy} =0.631), and were not significantly modified after cross-validation correction (R²=0.182, D_{xy} =0.657). The score was then validated using the remaining 20% of the population (n=3,105, deaths=297); we observed that the score retained its predictive and discriminative ability (R²=0.141, C-statistic=0.801, D_{xy} =0.602) as did the categories (R²=0.144, C-statistic=0.792, D_{xy} =0.585). Distribution of the score significantly discriminates between lethal and non-lethal COVID-19 cases (**Figure 4**).

DISCUSSION

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

Our results demonstrate that diabetes, particularly early onset diabetes mellitus, obesity and comorbidity burden modify risk profiles in patients with COVID-19 infection in Mexico and significantly improve mortality prediction related to COVID-19 lethality. These findings position the notion that early-onset type 2 diabetes might carry a higher risk of mortality in vounger patients, which is similar to older patients with comorbidities and only higher in older patients with diabetes. Furthermore, our results suggest that obesity is a COVID-19 specific risk factor for mortality, risk of ICU admission, tracheal intubation and hospitalization and even increases risk in patients with diabetes and COVID-19 infection. Overall, this positions the co-existence of obesity and diabetes, particularly early-onset diabetes, as a considerable risk factor for COVID-19 mortality in Mexicans, whom have reported an alarmingly high burden of both conditions in recent health surveys. The relationship between increased risk of mortality attributable to acute severe respiratory infections in patients with diabetes mellitus has been extensively reported, particularly for the acute respiratory syndrome caused by SARS-CoV-1 [16-18]. Evidence relating SARS-CoV-2 infections in China demonstrated increased rates of diabetes mellitus in hospitalized patients and in those with increased disease severity as assessed by ICU admission and requirement

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

for invasive ventilation. Additionally, hospitalized patients have shown increased rates of both obesity and diabetes for COVID-19 compared to non-hospitalized cases in the US, China and Italy [5,19,20]. Increased susceptibility for COVID-19 in patients with diabetes may be explained for several potential mechanisms including an increased lung ACE2 expression and elevated circulating levels of furin, a protease involved in viral entry to cells, and a decreased clearance of SARS-CoV-2 viral particles in subjects with diabetes and/or hypertension associated with ACE2 expression [21–24]. Impairments in immunity observed in patients with diabetes are characterized by initial delay in activation of Th1 cell-mediated immunity and late hyper-inflammatory response and are consistent with the increased risk associated with additional immunosuppression observed with our data [25]. Additional factors which have been proposed to modify COVID-19 mortality risk and worsen glycemic control in diabetes include corticosteroid therapy, inadequate glucose monitoring, the effect of social distancing on diabetes care and the use of antihypertensive medication; however these factors remain to be confirmed by clinical evidence [26]. Given the large proportion of undiagnosed diabetes cases in Mexican and poor glycemic control reported by recent estimates, the burden of COVID-19 might be higher than expected in Mexico and poses a challenge for the Mexican healthcare system to give particular attention to this sector as the epidemic moves forward [27–29]. Diabetes mellitus is one of the main causes of morbidity and it accounts for a large proportion of mortality risk in Mexican population [4]. Of relevance, Mexicans have increased risk of diabetes and diabetes-related obesity attributable to genetic variants associated to its Amerindian ancestry, and an earlier age of onset independent of body-mass index [30,31]. Data on the incidence of early-onset type 2 diabetes in Mexican population position obesity and insulin resistance as significant risk factors, which are also highly prevalent in younger patients and increase metabolic risk [32,33]. These associations partly explain the increased risk of COVID-19 lethality in younger patients within our cohort despite the younger average

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

age of Mexican population and poses early-onset diabetes mellitus as a significant risk factor for COVID-19 mortality and increased severity of infection in younger patients [5,34]. In our work, we demonstrate that compared to non-COVID-19 infections, obesity significantly modifies the risk of mortality attributable to COVID-19 infection. Obesity and, in particular, abdominal obesity, is one of Mexico's main public health problems; in recent years the socioeconomic burden of obesity as well as its impact on mortality have increased drastically, with the Ministry of Health declaring a state of epidemiological emergency [35]. Evidence from different regions has supported the notion that obesity increases mortality risk and severity of COVID-19 infections, which holds particularly true for younger patients [2,36]. Obesity is characterized by a low-grade state of inflammation and may impair immune response which in turn also may affect the lung parenchyma, increasing the risk for inflammatory lung diseases [37,38]. In particular, abdominal obesity reduces the compliance of lung, chest wall and entire respiratory system, resulting in impaired ventilation of the base of the lungs and reduced oxygen saturation of blood [39]. Recently, Simonnet et al. explored the high prevalence of obesity in patients with COVID-19 reporting that obesity is a risk factor for SARS-CoV-2 infection severity independent of age, diabetes and hypertension. Notably, ACE2 expression in adipose tissue is higher than in the lung and its expression profile is not different in obese and non-obese subjects; however, obese subjects have more adipocytes; thus, they have a greater number of ACE2-expressing cells and thus higher likelihood of SARS-CoV-2 entry [2,40]. Our data shows that obesity is a specific risk factor for COVID-19 related outcomes and that it partly mediates the risk associated with diabetes mellitus. Public health efforts by the Mexican government in epidemiological surveillance have largely focused in identifying patient's at highest risk of complications; these findings could inform public health decisions and increase awareness on the role of obesity in modifying risk of COVID-18 outcomes.

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

Our study had some strengths and limitations. First, we analyzed a large dataset which included information on both confirmed positive and negative SARS-CoV-2 cases, which provides a unique opportunity to investigate COVID-19 specific risk factors and develop a predictive model for COVID-19 mortality. Additionally, with the database being nationallyrepresentative it allows for reasonable estimates on the impact of both diabetes and obesity despite the possibility of important regional differences in cardiometabolic risk which might influence risk estimates. A potential limitation of this study is the use of data collected from a sentinel surveillance system model, which is skewed towards investigating high risk cases or only those with specific risk factors which on one hand increases power to detect the effect of comorbidities and on the other hand might not be representative of milder cases of the disease; this is demonstrated in the risk of COVID-19 positivity, which is higher for high risk cases. The updating daily estimates of COVID-19 cases are unlikely to change the direction of the identified associations though it might modify numeric estimates. Implementation of our proposed model might be useful to allocate prompt responses to high risk cases and improve stratification of disease severity. In conclusion, we show that both diabetes and obesity increase the risk of SARS-CoV-2 infection in Mexico. In particular, diabetes increases the risk of COVID-19 related mortality and, specifically, increases mortality risk in early-onset cases. Obesity is a COVID-19 specific risk factor for mortality and for increased disease severity; obesity also is a partial mediator on the effect of diabetes in decreasing survival associated with COVID-19 infection. This mechanistic interpretation on the risk of comorbidities allowed the development of a model with good performance to predict mortality in COVID-19 cases. Given the burden of obesity and diabetes in Mexico, COVID-19 lethality might be higher in younger cases. Special attention should be given to susceptible individuals and screening should be conducted for all symptomatic cases with either obesity and/or diabetes to decrease the burden associated with COVID-19 in Mexico.

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

Conflict of interest: Nothing to disclose. Role of the funding source: This research received no funding. **ACKNOWLEDGMENTS** JPBL, AVV, NEAV, AMS and CAFM are enrolled at the PECEM program of the Faculty of Medicine at UNAM. JPBL and AVV are supported by CONACyT. The authors would like to acknowledge the invaluable work of all of Mexico's healthcare community in managing the COVID-19 epidemic. Its participation in the COVID-19 surveillance program has made this work a reality, we are thankful for your effort. **DATA AVAILABILITY** All data sources and R code are available for reproducibility of results at https://github.com/oyaxbell/covid_diabetesmx. **AUTHOR CONTRIBUTIONS** Research idea and study design OYBC, JPBL, CAAS; data acquisition: OYBC, AGD; data analysis/interpretation: OYBC, JPBL, NEAV, AVV, AGD, JJN, CAAS; statistical analysis: OYBC, NEAV; manuscript drafting: OYBC, NEAV, AVV, JPBL, AMS, CAFM, JJN; supervision or mentorship: OYBC, CAAS. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. **FUNDING:** No funding was received. **CONFLICT OF INTEREST/FINANCIAL DISCLOSURE:** Nothing to disclose. REFERENCES Información Internacional y Nacional sobre nuevo Coronavirus (COVID-2019) 1. Secretaría de Salud | Gobierno | gob.mx [Internet]. [cited 19 Apr 2020]. Available: https://www.gob.mx/salud/documentos/informacion-internacional-y-nacional-sobrenuevo-coronavirus-2019-ncov

358 2. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High 359 prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-360 2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020: 361 doi:10.1002/obv.22831 Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for 362 3. 363 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395: 1054-1062. doi:10.1016/S0140-6736(20)30566-3 364 Bello-Chavolla OY, Rojas-Martinez R, Aquilar-Salinas CA, Hernández-Avila M. 365 4. Epidemiology of diabetes mellitus in Mexico. Nutr Rev. 2017;75: 4–12. 366 doi:10.1093/nutrit/nuw030 367 368 5. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline 369 Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to 370 ICUs of the Lombardy Region, Italy. JAMA. 2020; doi:10.1001/jama.2020.5394 371 6. Muller LMAJ, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AlM, et al. 372 Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. 373 Clin Infect Dis. 2005;41: 281–288. doi:10.1086/431587 Van Kerkhove MD, Vandemaele KAH, Shinde V, Jaramillo-Gutierrez G, Koukounari A, 374 7. 375 Donnelly CA, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) 376 infection: a global pooled analysis. PLoS Med. 2011;8: e1001053. doi:10.1371/journal.pmed.1001053 377 Luzi L, Radaelli MG. Influenza and obesity: its odd relationship and the lessons for 378 8. COVID-19 pandemic. Acta Diabetol. 2020; doi:10.1007/s00592-020-01522-8 379 380 9. Jose RJ, Manuel A. Does COVID-19 Disprove the Obesity Paradox in ARDS? Obesity 381 (Silver Spring). 2020; doi:10.1002/oby.22835 Dietz W, Santos-Burgoa C. Obesity and its Implications for COVID-19 Mortality. Obesity 382 10. (Silver Spring). 2020; doi:10.1002/oby.22818 383

384 Shamah-Levy T, Campos-Nonato I, Cuevas-Nasu L, Hernández-Barrera L, Morales-385 Ruán MDC, Rivera-Dommarco J, et al. [Overweight and obesity in Mexican vulnerable 386 population. Results of Ensanut 100k]. Salud Publica Mex. 2019;61: 852–865. 387 doi:10.21149/10585 Moore BJB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020; 388 12. 389 eabb8925. doi:10.1126/science.abb8925 Datos Abiertos - Dirección General de Epidemiología | Secretaría de Salud | Gobierno | 390 gob.mx [Internet]. [cited 18 Apr 2020]. Available: 391 392 https://www.gob.mx/salud/documentos/datos-abiertos-152127?idiom=es 393 Secretaría de Salud Subsecretaría de Prevención y Promoción de la Salud Dirección 394 General de Epidemiología. LINEAMIENTOESTANDARIZADO PARA LA VIGILANCIA 395 EPIDEMIOLÓGICA Y POR LABORATORIO DE LAENFERMEDAD RESPIRATORIA 396 VIRAL. Apr 1, 2020. 15. 397 Cho S-H, Huang Y-T. Mediation analysis with causally ordered mediators using Cox 398 proportional hazards model. Stat Med. 2019;38: 1566-1581. doi:10.1002/sim.8058 Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and 399 diabetes are independent predictors for mortality and morbidity in patients with SARS. 400 401 Diabet Med. 2006;23: 623–628. doi:10.1111/j.1464-5491.2006.01861.x 402 17. Bello-Chavolla OY, Bahena-Lopez JP, Garciadiego-Fosass P, Volkow P, Garcia-Horton A, Velazquez-Acosta C, et al. Bloodstream infection caused by S. aureus in patients 403 with cancer: a 10-year longitudinal single-center study. Support Care Cancer. 2018;26: 404 4057-4065. doi:10.1007/s00520-018-4275-1 405 406 Akbar DH. Bacterial pneumonia: comparison between diabetics and non-diabetics. Acta 18. 407 Diabetol. 2001;38: 77-82. doi:10.1007/s005920170017 CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected 408

Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United

410 States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69: 382-411 386. doi:10.15585/mmwr.mm6913e2 412 20. Liang W-H, Guan W-J, Li C-C, Li Y-M, Liang H-R, Zhao Y, et al. Clinical characteristics 413 and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China. Eur Respir J. 2020; 414 415 doi:10.1183/13993003.00562-2020 Chen X, Hu W, Ling J, Mo P, Zhang Y, Jiang Q, et al. Hypertension and Diabetes Delay 416 417 the Viral Clearance in COVID-19 Patients. medRxiv. 2020: doi:10.1101/2020.03.22.20040774 418 Rao S, Lau A, So H-C. Exploring diseases/traits and blood proteins causally related to 419 22. 420 expression of ACE2, the putative receptor of 2019-nCov: A Mendelian Randomization 421 analysis. medRxiv. 2020; doi:10.1101/2020.03.04.20031237 Fernandez C, Rysä J, Almgren P, Nilsson J, Engström G, Orho-Melander M, et al. 422 23. 423 Plasma levels of the proprotein convertase furin and incidence of diabetes and 424 mortality. J Intern Med. 2018;284: 377–387. doi:10.1111/joim.12783 Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM 425 structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367: 426 427 1260-1263. doi:10.1126/science.abb2507 428 25. Hodgson K, Morris J, Bridson T, Govan B, Rush C, Ketheesan N. Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial 429 infections. Immunology. 2015;144: 171-185. doi:10.1111/imm.12394 430 Klonoff DC, Umpierrez GE. COVID-19 in patients with diabetes: risk factors that 431 26. 432 increase morbidity. Metab Clin Exp. 2020; 154224. doi:10.1016/j.metabol.2020.154224 Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, 433 27. pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 434 435 2020;14: 303-310. doi:10.1016/j.dsx.2020.04.004

436 Campos-Nonato I, Ramírez-Villalobos M, Flores-Coria A, Valdez A, Monterrubio-Flores 28. 437 E. Prevalence of previously diagnosed diabetes and glycemic control strategies in Mexican adults: ENSANUT-2016. PLoS One. 2020;15: e0230752. 438 439 doi:10.1371/journal.pone.0230752 Puig-Domingo M, Marazuela M, Giustina A. COVID-19 and endocrine diseases. A 440 29. 441 statement from the European Society of Endocrinology. Endocrine. 2020; doi:10.1007/s12020-020-02294-5 442 SIGMA Type 2 Diabetes Consortium, Williams AL, Jacobs SBR, Moreno-Macías H, 443 30. Huerta-Chagoya A, Churchhouse C, et al. Sequence variants in SLC16A11 are a 444 common risk factor for type 2 diabetes in Mexico. Nature. 2014;506: 97–101. 445 446 doi:10.1038/nature12828 447 Almeda-Valdes P, Gómez Velasco DV, Arellano Campos O, Bello-Chavolla OY, Del Rocío Sevilla-González M, Viveros Ruiz T, et al. The SLC16A11 risk haplotype is 448 449 associated with decreased insulin action, higher transaminases and large-size 450 adipocytes. Eur J Endocrinol. 2019;180: 99-107. doi:10.1530/EJE-18-0677 Arellano-Campos O, Gómez-Velasco DV, Bello-Chavolla OY, Cruz-Bautista I, 451 32. Melgarejo-Hernandez MA, Muñoz-Hernandez L, et al. Development and validation of a 452 453 predictive model for incident type 2 diabetes in middle-aged Mexican adults: the 454 metabolic syndrome cohort. BMC Endocr Disord. 2019;19: 41. doi:10.1186/s12902-019-0361-8 455 Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, García E, Valles V, Ríos-Torres JM, et 456 33. al. Prevalence and characteristics of early-onset type 2 diabetes in Mexico. Am J Med. 457 458 2002:113: 569-574. doi:10.1016/s0002-9343(02)01314-1 Jiménez-Corona A, Rojas R, Gómez-Pérez FJ, Aguilar-Salinas CA. Early-onset type 2 459 34. diabetes in a Mexican survey: results from the National Health and Nutrition Survey 460

461 2006. Salud Publica Mex. 2010;52 Suppl 1: S27-35. doi:10.1590/s0036-462 36342010000700006 463 35. Nieto C, Tolentino-Mayo L, Monterrubio-Flores E, Medina C, Patiño SR-G, Aguirre-464 Hernández R, et al. Nutrition Label Use Is Related to Chronic Conditions among 465 Mexicans: Data from the Mexican National Health and Nutrition Survey 2016. J Acad 466 Nutr Diet. 2019; doi:10.1016/j.jand.2019.07.016 Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in 467 36. patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin 468 469 Infect Dis. 2020; doi:10.1093/cid/ciaa415 470 Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. Int J Obes. 37. 471 2013;37: 333–340. doi:10.1038/ijo.2012.62 472 38. Zhang X, Zheng J, Zhang L, Liu Y, Chen GP, Zhang HP, et al. Systemic inflammation 473 mediates the detrimental effects of obesity on asthma control. Allergy Asthma Proc. 474 2017; doi:10.2500/aap.2017.38.4096 475 39. Dixon AE, Peters U. The effect of obesity on lung function. Expert Rev Respir Med. 476 2018;12: 755-767. doi:10.1080/17476348.2018.1506331 477 40. Jia X, Yin C, Lu S, Chen Y, Liu Q, Bai J, et al. Two Things about COVID-19 Might Need 478 Attention. 2020; doi:10.20944/preprints202002.0315.v1

Table 1. Descriptive statistics comparing negative, positive and suspected cases for SARS-CoV-2 in Mexico at 04/27/2020.

**Abbreviations: ICU= intense care unit; COPD= chronic obstuctive pulmonary disease; CKD= chronic kidney disease; CVD= cardiovascular disease.

Daramatar	Positive for SARS-CoV-2	Negative for SARS-CoV-2	Suspected for SARS-CoV-2 n=8614		
Parameter	n=15529	n=46960			
Age (mean ± sd)	46.55±15.51	39.56±17.9	43.22±17.27		
Male sex (%)	8977(57.8)	21955(46.8)	4664(54.1)		
Mortality (%)	1434(9.2)	881(1.9)	137(1.6)		
Hospitalization (%)	6042(38.9)	9974(21.2)	2607(30.3)		
Pneumonia (%)	4588(29.5)	6341(13.5)	1841(21.4)		
ICU admission (%)	676(4.4)	774(1.6)	211(2.4)		
Invasive ventilation (%)	669(4.3)	598(1.3)	197(2.3)		
Diabetes (%)	2831(18.2)	5163(11)	1323(15.4)		
COPD (%)	389(2.5)	1330(2.8)	214(2.5)		
Asthma (%)	542(3.5)	2571(5.5)	337(3.9)		
Immunosuppression (%)	296(1.9)	1402(3)	183(2.1)		
Hypertension (%)	3370(21.7)	7353(15.7)	1611(18.7)		

Parameter	Positive for SARS-CoV-2	Negative for SARS-CoV-2	Suspected for SARS-CoV-2
Farameter	n=15529	n=46960	n=8614
Obesity (%)	3215(20.7)	6570(14)	1532(17.8)
CKD (%)	359(2.3)	1130(2.4)	262(3)
CVD (%)	453(2.9)	1610(3.4)	267(3.1)
Smoking (%)	1374(8.8)	4835(10.3)	811(9.4)

Table 2. Cox proportional risk models for lethality using the mechanistic COVID-19 lethality score in confirmed cases of COVID-19 using individual components, single score point and risk stratification categories. Abbreviations: COPD= chronic obstructive pulmonary disease; CKD= chronic kidney disease; CVD= cardiovascular disease.

								Р
								V
Model	Parameter	В	Score	SE	Wald	HR	95% CI	al
								u
								е
	Age ≥65 years	0.753	3	0.065	11.568	2.12	1.87-2.41	<0.001
Individual variables C-statistic= 0.828	Pregnancy	0.963	4	0.451	2.133	2.62	1.08-6.35	0.033
	Diabetes	0.251	1	0.066	3.802	1.29	1.13-1.46	<0.001
	Diabetes*Age <40 years	1.092	4	0.265	4.119	2.98	1.77-5.01	<0.001
	Age <40 years	-1.397	-6	0.136	-10.283	0.25	0.19-0.32	<0.001
	Obesity	0.374	1	0.066	5.680	1.45	1.28-1.65	<0.001
	Pneumonia	1.697	7	0.072	23.444	5.46	4.74-6.29	<0.001

	- CKD	0.568	2	0.120	4.179	1.76	1.39-2.23	<0.001
	COPD	0.277	1	0.117	2.361	1.32	1.05-1.66	0.018
	Immunosuppression	0.500	2	0.137	3.365	1.65	1.26-2.16	<0.001
Score point training C-statistic= 0.829	1-Point increment	0.24	6	0.007	36.15	1.28	1.26-1.30	<0.001
	Low-Risk (0 pts)				Referen	ce		
Risk Categories	Low-Risk (0 pts) Mild-Risk (1-3 pts)	1.87	3	0.136	Reference	ce 6.51	4.98-8.50	<0.001
Risk Categories training	,	1.87 2.72		0.136 0.131			4.98-8.50 11.83-19.75	<0.001 <0.001
•	Mild-Risk (1-3 pts)		7		13.73	6.51		

FIGURE LEGENDS




Figure 1. Cox proportional risk regression analysis to evaluate lethality of SARS-CoV-2 in Mexico, compared to SARS-CoV2 negative cases for all suspected cases with SARS-CoV2 status available (A) and stratified by diabetes mellitus (B) and obesity (C). *Abbreviations*: ICU= intense care unit; COPD= chronic obstructive pulmonary disease; CKD= chronic kidney disease; CVD= cardiovascular disease, HR= Hazard ratio.




Figure 2. Kaplan-Meier survival curves to evaluate lethality of SARS-CoV-2 positivity in patients with diabetes and comorbidities (A), diabetes and obesity (B), obesity and comorbidities (C) and diabetes with age 40 years (D). Abbreviations: DM= Diabetes mellitus; OB= Obesity; Comorb= Comorbidities.




Figure 3. Logistic regression analyses to evaluate COVID-19 related outcomes in all patients with SARS-CoV2 positivity for admission to ICU (A), mechanical ventilation (B) and hospital admission risk (C).




Figure 4. Symptom onset among lethal and non-lethal cases in new-confirmed COVID 19 cases, stratified by diabetes and obesity status (A), density histogram of scores of the mechanistic COVID-19 score (B). Points and score intervals considered for clinical score scale (C) and Kaplan-Meir Survival analysis curves to evaluate lethality using risk categories in the training (D) and validation cohorts (E). Abbreviations: OB= Obesity; DM= Diabetes mellitus; CKD= chronic kidney disease; COPD= Chronic obstructive pulmonary disease.